ベクティビックス（パニツムマブ）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

ベクティビックス（パニツムマブ）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8％で18億5,390万米ドルに成長します。予測期間の成長は、転移性結腸直腸がん（mcrc）の世界の有病率の増加、個別化医療への注目の高まり、新興市場におけるヘルスケア支出の増加、腫瘍学における生物製剤の採用拡大、患者のQOLへの注目の高まりなどに起因すると考えられます。予測期間における主要動向としては、抗EGFR療法の進歩、製薬企業間の提携や共同研究、先進診断ツールの統合、コンパニオン診断薬の開発、次世代シーケンサーの採用などが挙げられます。

大腸がんの有病率の増加は、今後数年間のベクティビックス（パニツムマブ）市場の成長を牽引すると予想されます。結腸や直腸から始まる大腸がんは、加齢、遺伝的素因、環境の影響などの要因に影響されます。大腸がんの罹患率の上昇は、人口の高齢化、生存率の向上、検出方法の改善に関連しています。モノクローナル抗体であるベクティビックス（パニツムマブ）は、上皮成長因子受容体（EGFR）を標的として阻害し、野生型KRAS腫瘍患者の腫瘍の成長と進行を遅らせる。これは、従来型化学療法に反応しない患者に対する有効な治療法です。世界保健機関（WHO）によると、大腸がんの世界の負担は2040年までに大幅に増加し、年間320万人が新たに罹患すると予想されており、これは63％の増加です。このような有病率の増加は、ベクティビックスの需要を牽引することになると考えられます。

個別化医療に対する需要の高まりは、ベクティビックス（パニツムマブ）市場の成長を促進する重要な要因です。個別化医療は、遺伝子プロファイルを含む個々の患者の特性に基づいて治療を調整するものです。ゲノム技術の進歩、分子生物学に対する理解の向上、精密診断ツールの利用可能性により、個別化治療はより一般的なものとなっています。ベクティビックスは、特に腫瘍が野生型EGFRを発現している患者において、がん細胞上のEGFRを標的とすることにより、転移性大腸がんの個別化治療として使用されます。この標的アプローチは治療効果を高め、副作用を最小限に抑えます。例えば、2023年2月、個別化医療連合は、FDAが体外診断検査のいくつかの重要な適応症を承認したことを強調し、個別化医療の需要の高まりに貢献しています。この動向はベクティビックス市場の成長をさらに後押しします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のベクティビックス（パニツムマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のベクティビックス（パニツムマブ）市場：成長率分析
• 世界のベクティビックス（パニツムマブ）市場の実績：規模と成長、2019～2024年
• 世界のベクティビックス（パニツムマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のベクティビックス（パニツムマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のベクティビックス（パニツムマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 世界のベクティビックス（パニツムマブ）市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 大腸がんの治療
• その他のがん治療
• 世界のベクティビックス（パニツムマブ）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来手術センター

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のベクティビックス（パニツムマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のベクティビックス（パニツムマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ベクティビックス（パニツムマブ）市場：競合情勢
• ベクティビックス（パニツムマブ）市場：企業プロファイル
  • Amgen Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ベクティビックス（パニツムマブ）市場、2029年：新たな機会を提供する国
• ベクティビックス（パニツムマブ）市場、2029年：新たな機会を提供するセグメント
• ベクティビックス（パニツムマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Vectibix (panitumumab) is a monoclonal antibody used to treat metastatic colorectal cancer (mCRC). It targets the epidermal growth factor receptor (EGFR), a protein found on the surface of certain cancer cells. By binding to EGFR, panitumumab prevents its activation by natural growth factors, thereby inhibiting the signaling pathways that promote cell division and tumor growth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key distribution channels for vectibix include hospital pharmacies and online pharmacies. Hospital pharmacies provide medications to both inpatients and outpatients within healthcare facilities as part of integrated medical care. The drug is primarily used for treating colorectal cancer and other cancer types, with end-users including hospitals, clinics, and ambulatory surgical centers.

The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides vectibix (panitumumab) market statistics, including vectibix (panitumumab) industry global market size, regional shares, competitors with a vectibix (panitumumab) market share, detailed vectibix (panitumumab) market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. This vectibix (panitumumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $1,853.9 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing prevalence of metastatic colorectal cancer (mcrc) globally, growing focus on personalized medicine, increasing healthcare spending in emerging markets, growing adoption of biologics in oncology, increasing focus on patient quality of life. Major trends in the forecast period include advancements in anti-EGFR therapies, partnerships and collaborations between pharmaceutical companies, integration of advanced diagnostic tools, development of companion diagnostics, adoption of next-generation sequencing.

The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods. Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix.

The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common. Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market.

A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit. In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth.

The Key player operating in the vectibix (panitumumab) market is Amgen Inc.

North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vectibix (panitumumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vectibix (panitumumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vectibix (panitumumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vectibix (panitumumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vectibix (panitumumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vectibix (panitumumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
• 2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
• Companies Mentioned: Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vectibix (panitumumab) Market Characteristics

3. Vectibix (panitumumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Vectibix (panitumumab) Market Trends And Strategies

5. Vectibix (panitumumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Vectibix (panitumumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Vectibix (panitumumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Vectibix (panitumumab) Market Growth Rate Analysis
• 6.4. Global Vectibix (panitumumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Vectibix (panitumumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Vectibix (panitumumab) Total Addressable Market (TAM)

7. Global Vectibix (panitumumab) Market Pricing Analysis & Forecasts

8. Vectibix (panitumumab) Market Segmentation

• 8.1. Global Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• 8.2. Global Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer Treatment
• Other Cancer Treatments
• 8.3. Global Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers

9. Global Vectibix (panitumumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Vectibix (panitumumab) Market Regional And Country Analysis

• 10.1. Global Vectibix (panitumumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Vectibix (panitumumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Vectibix (panitumumab) Market

• 11.1. Asia-Pacific Vectibix (panitumumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Vectibix (panitumumab) Market

• 12.1. China Vectibix (panitumumab) Market Overview
• 12.2. China Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Vectibix (panitumumab) Market

• 13.1. India Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Vectibix (panitumumab) Market

• 14.1. Japan Vectibix (panitumumab) Market Overview
• 14.2. Japan Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Vectibix (panitumumab) Market

• 15.1. Australia Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Vectibix (panitumumab) Market

• 16.1. South Korea Vectibix (panitumumab) Market Overview
• 16.2. South Korea Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Vectibix (panitumumab) Market

• 17.1. Western Europe Vectibix (panitumumab) Market Overview
• 17.2. Western Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Vectibix (panitumumab) Market

• 18.1. UK Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Vectibix (panitumumab) Market

• 19.1. Germany Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Vectibix (panitumumab) Market

• 20.1. France Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vectibix (panitumumab) Market

• 21.1. Eastern Europe Vectibix (panitumumab) Market Overview
• 21.2. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Vectibix (panitumumab) Market

• 22.1. North America Vectibix (panitumumab) Market Overview
• 22.2. North America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Vectibix (panitumumab) Market

• 23.1. USA Vectibix (panitumumab) Market Overview
• 23.2. USA Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Vectibix (panitumumab) Market

• 24.1. Canada Vectibix (panitumumab) Market Overview
• 24.2. Canada Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Vectibix (panitumumab) Market

• 25.1. South America Vectibix (panitumumab) Market Overview
• 25.2. South America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Vectibix (panitumumab) Market

• 26.1. Middle East Vectibix (panitumumab) Market Overview
• 26.2. Middle East Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Vectibix (panitumumab) Market

• 27.1. Africa Vectibix (panitumumab) Market Overview
• 27.2. Africa Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Vectibix (panitumumab) Market Competitive Landscape And Company Profiles

• 28.1. Vectibix (panitumumab) Market Competitive Landscape
• 28.2. Vectibix (panitumumab) Market Company Profiles
  • 28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Vectibix (panitumumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Vectibix (panitumumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Vectibix (panitumumab) Market

32. Recent Developments In The Vectibix (panitumumab) Market

33. Vectibix (panitumumab) Market High Potential Countries, Segments and Strategies

• 33.1 Vectibix (panitumumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Vectibix (panitumumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Vectibix (panitumumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer